Remedy Pharmaceuticals
New York
About Remedy Pharmaceuticals
Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylurea receptor. The company was founded in 2004 and is based in New York, New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.5M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2017)
- Website: remedypharmaceuticals.com
- Phone: 212-586-2226
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/remedy-pharmaceuticals-189599 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.